Çetin Ordu, Professor of Medical Oncology at Demiroğlu Bilim University, shared on LinkedIn:
“The Oncotype DX Recurrence Score (ODX RS), which was previously found to be cost-effective based on the NSABP B-20 trial, has also been determined to be cost-effective according to the updated Tailor X trial.
Our prospective research article – conducted by the Florence Nightingale Breast Study Group and published in ‘BMC Health Services Research Journal’ – demonstrates the cost-effectiveness of this genomic test in patients with hormone receptor-positive, HER-2-negative, and node-negative (or micrometastatic) breast cancer.
These findings could pave the way for the reimbursement of genomic tests in Türkiye to guide decisions regarding adjuvant chemotherapy.”
Title: Comparison of Tailor X and NSABP-20 regarding cost-effectiveness of recurrence score (RS®) for adjuvant chemotherapy decision in early-stage breast cancer
Authors: Çetin Ordu, Enver Özkurt, Ertan Koç, Erhan Gökmen, Mustafa Özdoğan, Nilüfer Güler, Cihan Uras, Bahadır Öz, Abdurrahman Işıkdoğan, Orhan Demircan, Fulden Yumuk, Pınar Saip, Vahit Özmen
This can be interesting:
